Thelior Bio

Breakdown of barrier tissue homeostasis is a key driver of pathology in many inflammatory conditions. In inflammatory bowel disease (IBD) loss of epithelial barrier repair systems in the gut is a key driver of disease.

Thelior Bio is developing therapies to mediate repair of the gut’s epithelial barrier, treating a core driver of inflammation rather than just managing symptoms. The company’s approach could in future be applied to treat other immune-driven conditions such as atopic dermatitis and rheumatoid arthritis.